The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Engineered Design of Mesoporous Silica Nanoparticles to Deliver Doxorubicin and P-Glycoprotein siRNA to Overcome Drug Resistance in a Cancer Cell Line
Open accessAbstract
Overexpression of drug efflux transporters such as P-glycoprotein (Pgp) protein is one of the major mechanisms for multiple drug resistance (MDR) in cancer cells. A new approach to overcome MDR is to use a co-delivery strategy that utilizes a siRNA to silence the expression of efflux transporter together with an appropriate anticancer drug for drug resistant cells. In this paper, we report that mesoporous silica nanoparticles (MSNP) can be functionalized to effectively deliver a chemotherapeutic agent doxorubicin (Dox) as well as Pgp siRNA to a drug-resistant cancer cell line (KB-V1 cells) to accomplish cell killing in an additive or synergistic fashion. The functionalization of the particle surface with a phosphonate group allows electrostatic binding of Dox to the porous interior, from where the drug could be released by acidification of the medium under abiotic and biotic conditions. In addition, phosphonate modification also allows exterior coating with the cationic polymer, polyethylenimine, which endows the MSNP to contemporaneously deliver Pgp siRNA. The dual delivery of Dox and siRNA in KB-V1 cells was capable of increasing the intracellular as well as intranuclear drug concentration to levels exceeding that of free Dox or the drug being delivered by MSNP in the absence of siRNA codelivery. These results demonstrate that it is possible to use the MSNP platform to effectively deliver a siRNA that knocks down gene expression of a drug exporter that can be used to improve drug sensitivity to a chemotherapeutic agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Xia, T., Kovochich, M., Liong, M., Meng, H., Kabehie, S., George, S., Zink, J. I., & Nel, A. E. (2009) · ACS Nano · doi:10.1021/nn900918w · Cited by 933
Self-citation
Cited by
Mesoporous silica nanoparticles in biomedical applications
Li, Z., Barnes, J. C., Bosoy, A., Stoddart, J. F., & Zink, J. I. (2012) · Chemical Society Reviews · doi:10.1039/c1cs15246g · Cited by 1,907
Self-citationThe current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
He, C., Lu, K., Liu, D., & Lin, W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja4098862 · Cited by 885
Wang, F., Wang, Y.-C., Dou, S., Xiong, M.-H., Sun, T.-M., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn200007z · Cited by 813
Physicochemical Properties Determine Nanomaterial Cellular Uptake, Transport, and Fate
Zhu, M., Nie, G., Meng, H., Xia, T., Nel, A., & Zhao, Y. (2013) · Accounts of Chemical Research · doi:10.1021/ar300031y · Cited by 803
Self-citationNanoparticle decoration with surfactants: Molecular interactions, assembly, and applications
Heinz, H., Pramanik, C., Heinz, O., Ding, Y., Mishra, R. K., Marchon, D., Flatt, R. J., Estrela-Lopis, I., Llop, J., Moya, S., et al. (2017) · Surface Science Reports · doi:10.1016/j.surfrep.2017.02.001 · Cited by 608
Croissant, J. G., Fatieiev, Y., Almalik, A., & Khashab, N. M. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700831 · Cited by 594
Park, J., Wrzesinski, S. H., Stern, E., Look, M., Criscione, J., Ragheb, R., Jay, S. M., Demento, S. L., Agawu, A., Licona Limon, P., et al. (2012) · Nature Materials · doi:10.1038/nmat3355 · Cited by 494
Liang, C., Xu, L., Song, G., & Liu, Z. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00458j · Cited by 435
Nanoparticles for combination drug therapy
Ma, L., Kohli, M., & Smith, A. (2013) · ACS Nano · doi:10.1021/nn405674m · Cited by 367
Yu, M., Jambhrunkar, S., Thorn, P., Chen, J., Gu, W., & Yu, C. (2013) · Nanoscale · doi:10.1039/c2nr32145a · Cited by 316
Clemens, D. L., Lee, B.-Y., Xue, M., Thomas, C. R., Meng, H., Ferris, D., Nel, A. E., Zink, J. I., & Horwitz, M. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06049-11 · Cited by 260
Self-citationNanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178
“Indeed, Meng et al have reported that MSN can be functionalized to effectively deliver the chemotherapeutic agent DOX together with anti-Pgp siRNA to a drug-resistant cancer cell line (KB-V1 cells) to accomplish cell killing in an additive or synergistic fashion [49]”
BackgroundMethodHybrid nanoparticles for combination therapy of cancer
He, C., Lu, J., & Lin, W. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.029 · Cited by 174
Sun, R., Liu, Y., Li, S.-Y., Shen, S., Du, X.-J., Xu, C.-F., Cao, Z.-T., Bao, Y., Zhu, Y.-H., Li, Y.-P., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.018 · Cited by 172
Drug releasing nanoplatforms activated by alternating magnetic fields
Mertz, D., Sandre, O., & Bégin-Colin, S. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.02.025 · Cited by 119
Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs
Huang, W., Chen, L., Kang, L., Jin, M., Sun, P., Xin, X., Gao, Z., & Bae, Y. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.004 · Cited by 77
Boto, C., Quartin, E., Cai, Y., Martín-Lorenzo, A., Cenador, M. B. G., Pinto, S., Gupta, R., Enver, T., Sánchez-García, I., Hong, D., et al. (2017) · Nature Communications · doi:10.1038/ncomms15204 · Cited by 28
Sun, P., Leidner, A., Weigel, S., Weidler, P. G., Heissler, S., Scharnweber, T., & Niemeyer, C. M. (2019) · Small · doi:10.1002/smll.201900083 · Cited by 21
Metadata
- Authors
- Meng, H., Liong, M., Xia, T., Li, Z., Ji, Z., Zink, J. I., & Nel, A. E.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2010-07-14
- Volume
- 4
- Issue
- 8
- Pages
- 4539-4550
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2057256078
- Cited by
- 902
- References
- 3
- FWCI
- 27.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
